...sell its 12% stake to Angelini and remains eligible for milestones. Other investors in Arvelle include NovaQuest...

...the final $42.7 million tranche of Arvelle Therapeutics GmbH’s $133.3 million series A. Investors included NovaQuest...

...been left behind,” said CEO Patrick Jordan, who is also a partner at Mycovia investor NovaQuest...
...could have worldwide sales of up to $700 million. VT-1161 originated at Viamet Pharmaceuticals Inc. NovaQuest...
...Inc. with Jordan at the helm. While Mycovia is still majority owned and funded by NovaQuest...

...Therapeutics GmbH (Basel, Switzerland). The newco raised more than $100 million from a syndicate including NovaQuest...

...Korea). Arvelle is raising the money in a series A round from a syndicate including NovaQuest...

...Korea). Arvelle is raising the money in a series A round from a syndicate including NovaQuest...

...on Nov. 13, which Roivant says values the company at about $7 billion. New investors NovaQuest...

...fourth equity financing, which Roivant says values the company at about $7 billion. New investors NovaQuest...

...Sciences dermatology subsidiary of Roivant Sciences GmbH (Basel, Switzerland) received the $100 million investment from NovaQuest...
...NovaQuest Capital Management LLC, Raleigh, N.C. Business: Dermatology Alicia Parker GSK2894512, WBI-1001, tapinarof Roivant Sciences GmbH Aryl hydrocarbon receptor (AHR) NovaQuest...

...forming subunit of the large conductance potassium channel. Dermavant received the $100 million investment from NovaQuest...